Literature DB >> 14969674

A pilot study on the acceptability of levonorgestrel-releasing intrauterine device by young, single, nulliparous Chinese females following surgical abortion.

Chiu-fai Ivy Li1, S S N Lee, T C Pun.   

Abstract

This study investigated the acceptability of the levonorgestrel-releasing intrauterine device (LNG-IUS) as contraception among young, single women after termination of pregnancy. Twenty subjects, with a median age of 21 years, had LNG-IUS inserted immediately after suction termination of first-trimester pregnancy. The subjects were followed-up at 6 weeks, 3 months, 6 months and 12 months. Fifteen subjects (75%) had other pregnancies terminated in the past. There were no serious complications or pregnancies. The acceptability of the LNG-IUS was generally above 86% during each follow-up visit. A total of seven (35%) subjects were lost to follow-up at different periods of the study. Overall, four subjects (22%) had the LNG-IUS removed. Nine subjects were seen at the end of the 1-year study period and all continued with the LNG-IUS for contraception. Side effects were commonly observed and irregular vaginal bleeding was the most common. We conclude that the LNG-IUS may be an acceptable method among selective young, single, nulliparous clients after termination of pregnancy and could be offered as an option of contraception to them. However, the small sample size and the high lost-to-follow-up rate are the major limitations of this study.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14969674     DOI: 10.1016/j.contraception.2003.10.008

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  1 in total

1.  Acceptance of long-acting reversible contraceptive methods by adolescent participants in the Contraceptive CHOICE Project.

Authors:  Renee Mestad; Gina Secura; Jenifer E Allsworth; Tessa Madden; Qiuhong Zhao; Jeffrey F Peipert
Journal:  Contraception       Date:  2011-04-27       Impact factor: 3.375

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.